A bioresorbable biomaterial carrier and passive stabilization device to improve heart function post-myocardial infarction
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články
PubMed
31349422
DOI
10.1016/j.msec.2019.109751
PII: S0928-4931(18)32783-8
Knihovny.cz E-zdroje
- Klíčová slova
- Epicardial carrier device, Extravascular device, Hyaluronic acid hydrogel, Myocardial infarction, Stem cell delivery, Ventricular stabilization,
- MeSH
- biokompatibilní materiály MeSH
- buněčná a tkáňová terapie přístrojové vybavení metody MeSH
- design vybavení MeSH
- hydrogely aplikace a dávkování chemie farmakologie MeSH
- infarkt myokardu patofyziologie terapie MeSH
- kyselina hyaluronová MeSH
- lidé MeSH
- mezenchymální kmenové buňky * účinky léků MeSH
- perikard MeSH
- pohyb buněk účinky léků MeSH
- prasata MeSH
- transplantace mezenchymálních kmenových buněk MeSH
- tuková tkáň cytologie MeSH
- viskozita MeSH
- vstřebatelné implantáty * MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- biokompatibilní materiály MeSH
- hydrogely MeSH
- kyselina hyaluronová MeSH
The limited regenerative capacity of the heart after a myocardial infarct results in remodeling processes that can progress to congestive heart failure (CHF). Several strategies including mechanical stabilization of the weakened myocardium and regenerative approaches (specifically stem cell technologies) have evolved which aim to prevent CHF. However, their final performance remains limited motivating the need for an advanced strategy with enhanced efficacy and reduced deleterious effects. An epicardial carrier device enabling a targeted application of a biomaterial-based therapy to the infarcted ventricle wall could potentially overcome the therapy and application related issues. Such a device could play a synergistic role in heart regeneration, including the provision of mechanical support to the remodeling heart wall, as well as providing a suitable environment for in situ stem cell delivery potentially promoting heart regeneration. In this study, we have developed a novel, single-stage concept to support the weakened myocardial region post-MI by applying an elastic, biodegradable patch (SPREADS) via a minimal-invasive, closed chest intervention to the epicardial heart surface. We show a significant increase in %LVEF 14 days post-treatment when GS (clinical gold standard treatment) was compared to GS + SPREADS + Gel with and without cells (p ≤ 0.001). Furthermore, we did not find a significant difference in infarct quality or blood vessel density between any of the groups which suggests that neither infarct quality nor vascularization is the mechanism of action of SPREADS. The SPREADS device could potentially be used to deliver a range of new or previously developed biomaterial hydrogels, a remarkable potential to overcome the translational hurdles associated with hydrogel delivery to the heart.
AdjuCor GmbH Lichtenbergstr 8 85748 Garching Germany
Celyad SA Mont Saint Guibert Belgium
Explora Biotech Srl G Peroni 386 00131 Rome Italy
R and D Department Contipro Dolni Dobrouc 401 561 02 Dolni Dobrouc Czech Republic
Citace poskytuje Crossref.org